The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ivonescimab (ivo) with oxaliplatin + fluorouracil (5-FU) + leucovorin calcium (mFOLFOX6) for patients (pts) with unresectable metastatic colorectal cancer (mCRC): A phase 2 study.
 
David Berz
Employment - Valkyrie Clinical Trials
Leadership - Jazz Pharmaceuticals; Sun Pharma
Honoraria - EMD Serono; Sun Pharma
Research Funding - Ascendis Pharma; BeiGene; BioNTech; Black Diamond Therapeutics; Boehringer Ingelheim; Bristol Myers Squibb; eFFECTOR Therapeutics; Faeth Therapeutics; G1 Therapeutics; Genprex; Hongyun Biotech; Incyte; InhibRx; Mirati Therapeutics; Seagen; Summit Therapeutics; WhiteOak; Xencor
Travel, Accommodations, Expenses - EMD Serono; Jazz Pharmaceuticals
 
Yanhong Deng
No Relationships to Disclose
 
Jianwei Zhang
No Relationships to Disclose
 
Zhiwei Li
No Relationships to Disclose
 
Ming Yin
Employment - Summit Therapeutics
Stock and Other Ownership Interests - Summit Therapeutics
 
Junjie Zhao
Employment - Summit Therapeutics
Stock and Other Ownership Interests - Summit Therapeutics
 
Karl Eckert
Employment - Summit Therapeutics
Stock and Other Ownership Interests - Summit Therapeutics
Travel, Accommodations, Expenses - Summit Therapeutics
 
Nindhana Paranthaman
Employment - Summit Therapeutics
Stock and Other Ownership Interests - Summit Therapeutics
(OPTIONAL) Uncompensated Relationships - CLS; Society for Immunotherapy of Cancer
 
Xufang Yu
Employment - Akeso Biopharma
 
Yu Xia
Employment - Akeso Biopharma
Leadership - Akeso Biopharma
Stock and Other Ownership Interests - Akeso Biopharma
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Lilly; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); crispr therapeutics; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Revolution Medicines; Sanofi; Sanofi; Synthekine; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; lepu biopharma (Inst); Lilly (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Tango Therapeutics (Inst)